A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy

NCT05896371 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Cancer
Prostate Cancer
Metastatic Cancer
Metastatic Prostate Cancer

Interventions

DRUG: 177Lu-PSMA-I&T - escalating renal absorbed dose
DRUG: 177Lu-PSMA-I&T - recommended phase 2 regime

Sponsor

CHU de Quebec-Universite Laval

Collaborators

[object Object]